Overview

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-06-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether treatment with AZD9550 when given in combination with AZD6234 as once weekly subcutaneous (SC) injections is superior to placebo or either agent administered as monotherapy for weight loss in participants living with obesity or overweight with at least one weight-related co-morbidity.
Phase:
PHASE2
Details
Lead Sponsor:
AstraZeneca